Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has received an average rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports.

Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality- Global Phase 1 study of CLN-978 in systemic lupus ...

In 2024, Adimab and its partners initiated discovery on 62 new therapeutic programs, bringing the total number of ...

Cullinan Therapeutics, Inc. has a 1 year low of $9.91 and a 1 year high of $30.19. Get Cullinan Therapeutics alerts: Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last posted its ...

PRAX Praxis Precision Medicines, Inc.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...